(Reuters) – AstraZeneca (LON: AZN) announced on Tuesday that it has begun trials of a new antibody-based treatment and prevention of COVID-19.
The British pharmaceutical company, which is already at the forefront of developing a vaccine against COVID-19, said that early testing will determine how safe and well tolerated the AZD7442 cocktail, a combination of two monoclonal antibodies (mAbs), is. The tests are conducted on 48 healthy participants, aged 18 to 55.
If the results of the UK study are positive, AstraZeneca is poised to conduct broader trials of the next stages and test AZD7442 both as a preventive measure for healthy people and as a medicine for those already infected with COVID-19.
AstraZeneca, a London-based company, received $ 23.7 million from US government agencies in June to develop an antibody-based treatment for coronavirus.
(Pushkala Aripaka and Aakash Jagadesh Babu in Bangalore; translated by Olga Beskrovnova; edited by Anna Kozlova)